Eli Lilly and Company (NYSE: LLY) announced on October 15, 2025, that its experimental oral GLP-1 drug, orforglipron, achieved its primary and key secondary endpoints in two Phase 3 clinical trials, ACHIEVE-2 and ACHIEVE-5, for the treatment of type 2 diabetes. [1, 3, 5] The studies demonstrated that orforglipron provided superior blood sugar control and significant weight loss compared to both placebo and AstraZeneca's dapagliflozin, a commonly used SGLT-2 inhibitor. [1, 6] In the ACHIEVE-2 trial, orforglipron lowered A1C levels by up to 1.7%, compared to 0.8% for dapagliflozin. [3, 5] In the ACHIEVE-5 trial, when used with insulin glargine, it resulted in an additional 2.1% reduction in A1C. [3, 5] The company stated these results reinforce the drug's potential to become a new standard of care for individuals with type 2 diabetes. [4, 6] Lilly plans to submit orforglipron for global regulatory approval for type 2 diabetes in 2026, with a submission for the treatment of obesity anticipated by the end of 2025. [2, 4] The safety profile of orforglipron was consistent with previous studies, with the most common side effects being mild to moderate gastrointestinal issues. [2, 6]